// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

22,622
Stories Indexed
Live
Feed Status
6
Data Sources
LATEST
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 22,622 results Live
FDA STRIDES Jun 20 — 0.00

FDA Approves Unknown Drug — STRIDES PHARMA

1. **Analyze the Request:** * **Topic:** FDA drug approval. * **Input Data:** * Brand: N/A * Generic: N/A * Substance: [Missing from prom…

FDA LANNETT Jun 20 — 0.00

FDA Approves Unknown Drug — LANNETT CO INC

Lannett Co. Inc. has received FDA approval for ANDA 207171, which is expected to bolster its generic portfolio and contribute incremental revenue as the product enters the market.

FDA Lupin Jun 12 — 0.00

FDA Approves OXYCODONE HYDROCHLORIDE — Lupin Pharmaceuticals,Inc.

Lupin Pharmaceuticals, Inc. received FDA approval for its Oxycodone Hydrochloride generic on June 12, 2017, securing a position in the competitive opioid market and positioning the…

FDA SAGENT May 11 — 0.00

FDA Approves Unknown Drug — SAGENT PHARMS INC

# FDA Approves Generic Drug Application for Sagent Pharmaceuticals Sagent Pharmaceuticals Inc. received FDA approval for ANDA 203608 on May 11, 2017, expanding its generic drug po…

FDA KVK-TECH, May 11 — 0.00

FDA Approves METHYLPHENIDATE HYDROCHLORIDE — KVK-TECH, INC.

FDA approved KVK-TECH, Inc.’s abbreviated new drug application (ANDA) for methylphenidate hydrochloride, ramping up generic competition for the ADHD treatment. The approval is expe…

FDA Novartis May 4 — 0.00

FDA Approves KISQALI FEMARA CO-PACK — Novartis Pharmaceuticals Corporation

Novartis has secured FDA approval for the co-packaged fixed-dose combination of KISQALI and Femara (ribociclib and letrozole), a strategic move aimed at improving medication adhere…

FDA AstraZeneca May 1 — 0.00

FDA Approves IMFINZI — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's IMFINZI (Durvalumab) for Cancer Treatment AstraZeneca Pharmaceuticals LP has received FDA approval for IMFINZI (durvalumab), an intravenous immunother…

FDA RISING Apr 28 — 0.00

FDA Approves Unknown Drug — RISING

# FDA Approves Rising's Generic Drug Application The FDA approved ANDA200542 for Rising Pharmaceuticals on April 28, 2017, expanding the company's generic drug portfolio and posit…

FDA Apotex Apr 28 — 0.00

FDA Approves AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE — Apotex Corp.

On April 28, the FDA approved a generic version of the nasal spray AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE manufactured by Apotex Corp., representing significant market…

FDA Azurity Apr 25 — 0.00

FDA Approves XATMEP — Azurity Pharmaceuticals, Inc.

# FDA Approves Azurity Pharmaceuticals' XATMEP Oral Methotrexate Formulation Azurity Pharmaceuticals has received FDA approval for XATMEP (methotrexate), an oral formulation of th…

FDA Protega Apr 20 — 0.00

FDA Approves ROXYBOND — Protega Pharmaceuticals Inc

Protega Pharmaceuticals Inc. has received FDA approval for Roxycbond (oxycodone hydrochloride), a crucial strategic addition for the company intended to bolster its market portfoli…

FDA Unichem Apr 13 — 0.00

FDA Approves PIROXICAM — Unichem Pharmaceuticals (USA), Inc.

# FDA Approves Piroxicam Generic for Unichem Pharmaceuticals Unichem Pharmaceuticals (USA), Inc. received FDA approval for its generic piroxicam oral formulation, expanding the co…

FDA RISING Apr 7 — 0.00

FDA Approves Unknown Drug — RISING

# FDA Approves Rising Pharmaceuticals' Generic Drug Application Rising Pharmaceuticals has received FDA approval for an abbreviated new drug application (ANDA 207367), expanding i…

FDA RISING Apr 4 — 0.00

FDA Approves Unknown Drug — RISING

# FDA Approves Rising Pharmaceuticals' Generic Drug Application Rising Pharmaceuticals has received FDA approval for ANDA200217, expanding its generic drug portfolio and positioni…

FDA Genentech, Mar 28 — 0.00

FDA Approves OCREVUS — Genentech, Inc.

# FDA Approves Genentech's OCREVUS for Multiple Sclerosis Treatment Genentech announced FDA approval of OCREVUS (ocrelizumab), an intravenous monoclonal antibody therapy, position…

FDA Camber Mar 22 — 0.00

FDA Approves OXYCODONE AND ACETAMINOPHEN — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals gained FDA approval for its ANDA207419 formulation of oxycodone and acetaminophen tablets, granting the company the rights to supply a lower-cost alternative…

FDA Aurobindo Mar 22 — 0.00

FDA Approves TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN — Aurobindo Pharma Limited

The FDA has granted approval to Aurobindo Pharma Limited for its generic Tramadol Hydrochloride oral product, marking a new competitive entry into the opioid analgesic market. This…

FDA Accord Mar 21 — 0.00

FDA Approves OXALIPLATIN — Accord Healthcare Inc.

# FDA Approves Generic Oxaliplatin from Accord Healthcare Inc. Accord Healthcare Inc. received FDA approval for a generic version of oxaliplatin, an intravenous chemotherapy drug,…

FDA Ascend Mar 21 — 0.00

FDA Approves ROSUVASTATIN CALCIUM — Ascend Laboratories, LLC

On March 21, 2017, Ascend Laboratories, LLC received FDA approval for the ANDA for rosuvastatin calcium, a generic version of the widely used cholesterol-lowering drug. This route-…

FDA TEVA Mar 10 — 0.00

FDA Approves Unknown Drug — TEVA PHARMS USA

TEVA PHARMS USA reported the approval of its Abbreviated New Drug Application (ANDA 205807) on March 10, 2017, a milestone that positions the company to enter the generic market fo…